Psychedelics and Other Psychoplastogens for Treating Mental Illness

Maxemiliano V. Vargas(University of California, Davis), David E. Olson(Multidisciplinary Association for Psychedelic Studies), Mark Rus(Epix Pharmaceuticals (United States)), Arabo A. Avanes(University of California, Davis), Retsina Meyer(Epix Pharmaceuticals (United States))
Frontiers in Psychiatry
October 4, 2021
10.3389/fpsyt.2021.727117
Cited by 160

Related Papers

Psychedelics Promote Structural and Functional Neural Plasticity
|Cell Reports|2018|1.1k
A non-hallucinogenic psychedelic analogue with therapeutic potential
|Nature|2020|461
Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors
|Science|2023|455
The Subjective Effects of Psychedelics May Not Be Necessary for Their Enduring Therapeutic Effects
|ACS Pharmacology & Translational Science|2020|326
The neural basis of psychedelic action
|Nature Neuroscience|2022|286